AEON Biopharma (AEON) Operating Income (2021 - 2026)
AEON Biopharma (AEON) posted Operating Income of -$5.5 million for Q4 2025, down 121.06% sequentially from -$2.5 million in Q3 2025, and down 137.44% YoY from $14.7 million in Q4 2024.
AEON Biopharma (AEON) Operating Income (2021 - 2026) Analysis & Trends
AEON Biopharma has reported Operating Income for 5 years, with the latest figure at -$5.5 million in Q4 2025.
- Quarterly Operating Income fell 137.44% year-over-year to -$5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.8 million (down 117.54% YoY) and the FY2025 annual result came in at -$12.8 million, down 117.54% from the prior year.
- Operating Income eased to -$5.5 million in Q4 2025 per AEON's latest filing, from -$2.5 million in the prior quarter.
- Over five years, Operating Income peaked at $153.5 million in Q2 2024 and troughed at -$283.7 million in Q3 2023.
- A 5-year average of -$14.6 million and a median of -$2.5 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income plunged 3253.1% in 2023, then jumped 1198.51% in 2024.
- Over 5 years, Operating Income stood at -$885744.0 in 2021, then tumbled by 1597.22% to -$15.0 million in 2022, then tumbled by 1787.27% to -$283.7 million in 2023, then jumped by 99.18% to -$2.3 million in 2024, then plunged by 137.44% to -$5.5 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$5.5 million, -$2.5 million, and -$4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | AEON Biopharma | 9.73 Mn | 6.30 Mn | - | -5.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.92 Mn |
| Dec 31, 2025 | -5.51 Mn |
| Sep 30, 2025 | -2.49 Mn |
| Jun 30, 2025 | -4.34 Mn |
| Mar 31, 2025 | -462,000.00 |
| Dec 31, 2024 | -2.32 Mn |
| Sep 30, 2024 | -4.02 Mn |
| Jun 30, 2024 | 153.47 Mn |
| Mar 31, 2024 | -74.15 Mn |
| Sep 30, 2023 | -283.71 Mn |
| Jun 30, 2023 | -13.97 Mn |
| Mar 31, 2023 | -13.05 Mn |
| Dec 31, 2022 | -15.03 Mn |
| Sep 30, 2022 | -9.91 Mn |
| Jun 30, 2022 | -427,204.00 |
| Mar 31, 2022 | -389,073.00 |
| Dec 31, 2021 | -885,744.00 |
| Sep 30, 2021 | -450,892.00 |
| Jun 30, 2021 | -398,443.00 |
| Mar 31, 2021 | -200,863.00 |